Pneumocystis carinii pneumonia following discontinuation of primary prophylaxis despite highly active antiretroviral therapy

International Journal of STD and AIDS

Volumn 11, Issue 1, 2000, Pages 64-65

  Mammen Tobin, Amy ^a   Monteiro, Eric F ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

HAART; HIV; Pneumocystis carinii pneumonia; Primary prophylaxis

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CASE REPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; CD4 LYMPHOCYTE COUNT; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCYSTIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0033963591     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462001914805     Document Type: Article

References (6)

1. Pallela FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60
2. Feinberg J. Withdrawal of prophylaxis against Pneumocystis carinii pneumonia. Lancet 1999;353:1287
3. Weverling GJ, Morcroft A, Ledergerberg B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral treatment. Lancet 1999;353:93-8
4. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy. N Engl J Med 1993;340:1301-6
5. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with HIV-1. N Engl J Med 1990;322:161-5
6. Taylor JM, Fahey JL, Detels R, et al. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989;2:114-24